FORM 7
MONTHLY PROGRESS REPORT
For the Month of November, 2022

Name of CSE Issuer:	**Isracann Biosciences Inc.** (the "***Issuer***", the ***"Company"*** *or* ***"Isracann"***)
Trading Symbol:	**IPOT**
Number of Outstanding Listed Securities:	**175,989,944 common shares**
Date of filing:	**December 5, 2022**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   Company decided to shift the Company's focus to Praesidio's operations and consequently intends to abandon Cannation's operations. Both the Company and other venturer are not committing additional funds to further development of the project. While the joint venture continues to carry the property, plant and equipment with an intention to dispose of the asset through sale, management considers it uncertain whether this will occur based on the current market conditions locally. However, to maintain the right to the property, lease payments need to continue to be made to the lessor, should the company be unsuccessful in disposing of the asset through sale, it is unknown whether the Company will recover the carrying value of the assets.

2. Provide a general overview and discussion of the activities of management.

   Please see item 1.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether

the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see item 1.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   None.

7. Describe the acquisition of new customers or loss of customers.

   None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   None.

9. Report any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

   None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

    None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    None.

13. Provide details of any securities issued and options or warrants granted.

    Company closed 2nd tranche PP at 0.05 per unit total proceeds $50,050 with a warrant of $0.055 on November 4th 2022

14. Provide details of any loans to or by Related Persons.

    None.

15. Provide details of any changes in directors, officers or committee members.

    None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 6, 2022

Yana Popova
Name of Director or Senior Officer

"Yana Popova"
Signature

Chief Financial Officer
Official Capacity

Issuer Details		
Name of Issuer **Isracann Biosciences Inc.**	For Month End **November, 2022**	Date of Report YY/MM/DD **2022/12/05**
Issuer Address **1600 – 595 Burrard Street**		
City/Province/Postal Code **Vancouver, BC, V7C 1L4**	Issuer Fax No. ( )	Issuer Telephone No. **1 (604) 343-8661**
Contact Name: **Phil Floucault**	Contact Position: **CEO**	Contact Telephone No. **1 (250) 265-7076**